Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Offloads Xiidra As Expected, For $3.4bn Upfront To Novartis

Executive Summary

As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.

You may also be interested in...



Bausch + Lomb’s Dry Eye Pivotal Data Pave The Way For Spinout

B+L’s novel therapy for a subset of dry eye disease hits both sign and symptom endpoints in the first of two Phase III studies. The product could add value to a planned spinout.

Cheplapharm Benefits As Takeda Sheds More Older Products

Japanese major presses on with post-Shire divestments even after passing strategic target.

Novartis Pulls EU Marketing Application For Xiidra

Novartis recognized it would not be able to answer objections relating to its EU marketing application for the dry eye drug, Xiidra (lifitegrast), and so it has withdrawn the application. The company last year paid upwards of $3bn for the drug, which is already marketed in the US and other markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel